丹皮酚治疗肠道疾病作用机制研究进展

doi:10.3969/j.issn.1006-5725.2025.10.024

Abstract

Abstract:

As the lifestyle of modern people changes， genetic factors continue to become more prominent， and the impact of environmental and water pollution， the incidence of intestinal diseases （colorectal cancer， inflammatory bowel disease， irritable bowel syndrome， chronic constipation， etc.） is increasing. It not only seriously endangers the health of the population， but also consumes a large amount of medical resources. Paeonol， as a class of small molecule phenolic compounds， has a wide range of biological activities， such as anti-inflammatory， anti-viral， anti-tumor， anti-allergic， immune regulation， cardiovascular and cerebrovascular protection， etc. The mechanism and experimental research on the effect of paeonol in preventing and treating intestinal diseases based on the "Brain-Gut-Bacteria axis" are also in-depth. This article aims to systematically review and sort out the latest progress in this field， with a view to providing certain ideas and methods for the precise treatment of intestinal diseases and the development of new drugs.

Key words: paeonol, intestinal diseases, mechanism in the treatment, research progress

CLC Number:

R574.62

Wei WANG,Shihua LU,Honghao ZHANG,Hualiang. DENG. Research progress on mechanism of paeonol in the treatment of intestinal diseases[J]. The Journal of Practical Medicine, 2025, 41(10): 1597-1602.

Figures/Tables 1

References 39

1	杨山景，李凌军. 丹皮酚药理作用与应用研究进展［J］. 中药药理与临床，2022，38（5）：237-241.
2	孙菁菁，李张维，王玉栋. 丹皮酚的抗肿瘤作用及机制研究进展［J］. 中药新药与临床药理，2025，36（2）： 288-293.
3	YANG M， HAN J， YAN Z， et al. Paeonol attenuates LPS-induced inflammatory injury in mastitis by regulating the MAPK and Nrf2 signaling pathways［J］. Res Vet Sci， 2025， 182：105481. doi:10.1016/j.rvsc.2024.105481 doi: 10.1016/j.rvsc.2024.105481
4	何雨瞳. 基于TLR4/MyD88通路研究丹皮酚醚化脲类衍生物的抗炎机制及其构效关系［D］. 重庆：西南大学，2020.
5	陈根强，杨进明，孙迪，等. 丹皮酚苯磺酰腙类衍生物的合成及杀粘虫活性研究［J］. 化学通报， 2020，83（2）：139-143.
6	胡阳生. 新型丹皮酚衍生物的设计、合成、活性评价及构效关系研究［D］. 合肥：安徽医科大学， 2020.
7	张鲁宁. 丹皮酚通过调节肠道菌群介导的TGR5/PKA/CREB信号通路抑制酒精性肝损伤的作用机制［D］. 合肥：安徽中医药大学， 2024.
8	SHI X， HUANG H， ZHOU M， et al. Paeonol Attenuated Vascular Fibrosis Through Regulating Treg/Th17 Balance in a Gut Microbiota-Dependent Manner［J］. Front Pharmacol， 2021， 12：765482. doi:10.3389/fphar.2021.765482 doi: 10.3389/fphar.2021.765482
9	ZHAO M， XIE X， XU B， et al. Paeonol alleviates ulcerative colitis in mice by increasing short-chain fatty acids derived from Clostridium butyricum［J］. Phytomedicine， 2023，120：155056. doi:10.1016/j.phymed.2023.155056 doi: 10.1016/j.phymed.2023.155056
10	张宇欣. 基于LPS诱导的RAW264.7细胞炎症模型研究低毒性多酚类化合物抗炎作用及其分子机制［D］. 哈尔滨：哈尔滨商业大学，2023.
11	CHENG S， CHEN W， GUO Z， et al. Paeonol alleviates ulcerative colitis by modulating PPAR-γ and nuclear factor-κB activation［J］. Sci Rep， 2024，14（1）：18390. doi:10.1038/s41598-024-68992-6 doi: 10.1038/s41598-024-68992-6
12	ZONG S Y， PU Y Q， XU B L， et al. Study on the physicochemical properties and anti-inflammatory effects of paeonol in rats with TNBS-induced ulcerative colitis［J］. Int Immunopharmacol， 2017，42：32-38. doi:10.1016/j.intimp.2016.11.010 doi: 10.1016/j.intimp.2016.11.010
13	JIN X， WANG J， XIA ZM， et al. Anti-inflammatory and Anti-oxidative Activities of Paeonol and Its Metabolites Through Blocking MAPK/ERK/p38 Signaling Pathway［J］. Inflammation， 2016， 39（1）：434-446. doi:10.1007/s10753-015-0265-3 doi: 10.1007/s10753-015-0265-3
14	李淑芳，邓旭明. 丹皮酚对沙门氏菌Ⅲ型分泌系统的抑制作用及初步机制探讨［C］.//中国畜牧兽医学会兽医药理毒理学分会. 中国畜牧兽医学会兽医药理毒理学分会第十三次全国会员代表大会暨第十七次学术研讨会论文集. 长春：吉林大学动物医学学院， 2023：1.
15	KANG B， PARK D H， LEE M J， et al. Beneficial Effect of Paeonol on Antibiotic-Associated Inflammatory Response in Mice with Diarrhea［J］. Biomolecules， 2022，12（11）：1634. doi:10.3390/biom12111634 doi: 10.3390/biom12111634
16	CAMILLERI M， MADSEN K， SPILLER R， et al. Intestinal barrier function in health and gastrointestinal disease［J］. Neurogastroenterol Motil， 2012，24（6）：503-512. doi:10.1111/j.1365-2982.2012.01921.x doi: 10.1111/j.1365-2982.2012.01921.x
17	韩成龙，李苏阳，韩雅萌. 丹皮酚对5-FU诱导的小鼠肠道黏膜损伤的保护作用及对其抗肿瘤活性的影响［J］. 西部医学，2022，34（8）：1128-1132.
18	LOU Y， WANG C， TANG Q， et al. Paeonol Inhibits IL-1β-Induced Inflammation via PI3K/Akt/NF-κB Pathways： In Vivo and Vitro Studies［J］. Inflammation， 2017， 40（5）：1698-1706. doi:10.1007/s10753-017-0611-8 doi: 10.1007/s10753-017-0611-8
19	WU J， WU D， MA K， et al. Paeonol ameliorates murine alcohol liver disease via mycobiota-mediated Dectin-1/IL-1β signaling pathway［J］. J Leukoc Biol， 2020， 108（1）：199-214. doi:10.1002/jlb.3ma0120-325rr doi: 10.1002/jlb.3ma0120-325rr
20	WANG S， BAI M， SHU Q， et al. Modulating Effect of Paeonol on Piglets With Ulcerative Colitis［J］. Front Nutr， 2022， 9：846684. doi:10.3389/fnut.2022.846684 doi: 10.3389/fnut.2022.846684
21	DUDZIŃSKA E， GRABRUCKER A M， KWIATKOWSKI P， et al. The Importance of Visceral Hypersensitivity in Irritable Bowel Syndrome-Plant Metabolites in IBS Treatment［J］. Pharmaceuticals （Basel）， 2023，16（10）：1405. doi:10.3390/ph16101405 doi: 10.3390/ph16101405
22	PERNA E， AGUILERA-LIZARRAGA J， FLORENS M V， al et， Wouters M， Boeckxstaens G. Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS［J］. Gut，70（7）：1275-1286. doi:10.1136/gutjnl-2020-321530 doi: 10.1136/gutjnl-2020-321530
23	LI X， SHI H， ZHANG D， et al. Paeonol alleviates neuropathic pain by modulating microglial M1 and M2 polarization via the RhoA/p38MAPK signaling pathway［J］. CNS Neurosci Ther，2023， 29（9）：2666-2679. doi:10.1111/cns.14211 doi: 10.1111/cns.14211
24	CAI L， ZENG R， HUANG Q， et al. Paeonol inhibits chronic constriction injury-induced astrocytic activation and neuroinflammation in rats via the HDAC/miR-15a pathway［J］. Drug Dev Res，2022，83（8）：1758-1765. doi:10.1002/ddr.21993 doi: 10.1002/ddr.21993
25	QIU C， YANG L D， YU W， et al. Paeonol ameliorates CFA-induced inflammatory pain by inhibiting HMGB1/TLR4/NF-κB p65 pathway［J］. Metab Brain Dis， 2021， 36（2）：273-283. doi:10.1007/s11011-020-00645-9 doi: 10.1007/s11011-020-00645-9
26	窦鑫，贺昌辉，梅笑，等. 基于“短链脂肪酸-肠屏障”途径探讨中药在腹泻型肠易激综合征中的干预研究进展［J］. 实用医学杂志，2024，40（15）：2177-2182.
27	WANG X Y， VANNUCCHI M G， NIEUWMEYER F， et al. Changes in interstitial cells of Cajal at the deep muscular plexus are associated with loss of distention-induced burst-type muscle activity in mice infected by Trichinella spiralis［J］. Am J Pathol， 2005，167：437-453. doi:10.1016/s0002-9440(10)62988-4 doi: 10.1016/s0002-9440(10)62988-4
28	MENG Y， LIU Z， ZHAI C， et al. Paeonol inhibits the development of 1‑chloro‑2，4‑dinitrobenzene‑induced atopic dermatitis via mast and T cells in BALB/c mice［J］. Mol Med Rep， 2019， 19（4）：3217-3229.
29	ISHIGURO K， ANDO T， MAEDA O， et al. Paeonol attenuates TNBS-induced colitis by inhibiting NF-kappaB and STAT1 transactivation［J］. Toxicol Appl Pharmacol， 2006， 217（1）：35-42. doi:10.1016/j.taap.2006.07.002 doi: 10.1016/j.taap.2006.07.002
30	CHANG X， FENG X， DU M， et al. Pharmacological effects and mechanisms of paeonol on antitumor and prevention of side effects of cancer therapy［J］. Front Pharmacol， 2023， 14：1194861. doi:10.3389/fphar.2023.1194861 doi: 10.3389/fphar.2023.1194861
31	高吴陆怡，王静艳，舒岑皓，等. 基于网络药理学与分子对接的丹皮酚治疗结直肠癌的分子机制研究［J］. 中国医科大学学报，2023，52（11）：992-998.
32	LIU L H， SHI R J， CHEN Z C. Paeonol exerts anti‑tumor activity against colorectal cancer cells by inducing G0/G1 phase arrest and cell apoptosis via inhibiting the Wnt/β‑catenin signaling pathway［J］. Int J Mol Med， 2020， 46（2）：675-684. doi:10.3892/ijmm.2020.4629 doi: 10.3892/ijmm.2020.4629
33	程玉，李明，谭诗云，等. 丹皮酚对大肠癌细胞增殖、凋亡及自噬的影响［J］. 医学研究杂志， 2019，48（10）： 144-147.
34	MA L Y， XU X D， ZHANG Q， et al. Paeonol pharmacokinetics in the rat following i.m. administration［J］. Eur J Drug Metab Pharmacokinet， 2008，33（3）：133-136. doi:10.1007/bf03191109 doi: 10.1007/bf03191109
35	HU X， DING L， CAO S， et al. Pharmacokinetics， Tissue Distribution and Excretion of Paeonol and Its Major Metabolites in Rats Provide a Further Insight Into Paeonol Effectiveness［J］. Front Pharmacol， 2020，11：190. doi:10.3389/fphar.2020.00190 doi: 10.3389/fphar.2020.00190
36	LIU Q， XIA H， XU Y， et al. Investigation on the Preparation， Characteristics， and Controlled Release Model of Paeonol-Loaded Liposome in Carbomer Hydrogel［J］. Curr Drug Deliv， 2020，17（2）：159-173. doi:10.2174/1567201817666200115163506 doi: 10.2174/1567201817666200115163506
37	郑荣寿，陈茹，韩冰峰，等. 2022年中国恶性肿瘤流行情况分析［J］. 中华肿瘤杂志， 2024，46 （3）：221-231. doi:10.3760/cma.j.cn112152-20240119-00035 doi: 10.3760/cma.j.cn112152-20240119-00035
38	吴开春，梁洁，冉志华，等. 炎症性肠病诊断与治疗的共识意见（2018年北京）［J］. 中国实用内科杂志，2018，38（9）：796-813.
39	李彦楠，杨丽旋，赵钟辉，等. 《2020年中国肠易激综合征专家共识意见》解读［J］. 中国临床医生杂志，2021，49（10）：1151-1155.

机制	通路/机制	靶点
调节肠菌及其代谢物	Treg/Th17	SCFAs、胆汁酸组分、肠道菌群等
抗炎与抗菌	MAPK、NF-κB/p65	NO、TNF-α、IL-1β、IL-6、LCK、zap70、IKKα、IKKβ、iNOS、 COX-2、p-IκBα、p-p65、IFN-γ等
修复肠道屏障	Dectin-1/IL-1β、TGR5/PKA/CREB、NF-κB	Occludin、ZO-1、TGR5、cAMP、p-CREB、p-PKA、IGG、 TGF-β1、IL-10等
降低内脏高敏感	RhoA/p38MAPK、HDAC/MIR-15A、HMGB1/TLR4/ NF-κB-P65、PI3K-Akt-GSK3β-NF-κB	Trpv1、TNF-α、IL-1-MAMA等
增强肠黏膜免疫	T细胞受体通路、miR-155/JAK1-STAT1	辅助T细胞亚群、F4/80、CD86、IL-6、TNF-α等
肿瘤及耐药性	TLR4/MAPK/NF-κB、PI3K/Akt/NF-κB、SET/PP2A/Akt、 HIF-1α/VEGF、PI3K/Akt/mTOR、Fas/FasL、TCF/LEF	ERBB2、MMP-2、MMP-9、Notch1、SET、SRC、EP300、 Ras、Rap1、COX-2、P27、Bcl-1、Bcl-2、Atg5、LC3-Ⅱ等

[1]	Shan GAO,Kun JI,Li ZHAO,Yujia XING,Yandong XIE,Xiqiang CAI. Research progress on esophageal squamous intraepithelial neoplasia [J]. The Journal of Practical Medicine, 2024, 40(3): 432-438.
[2]	Ganggang LU,Shenglong LI,Yongqiang ZHAO,Yunpeng JIA,Yonglin LIANG,Yuanbo. ZHAO. Research progress on the correlation between oxidative stress and ferroptosis in diabetic impotence [J]. The Journal of Practical Medicine, 2024, 40(16): 2229-2235.
[3]	Xin DOU,Changhui HE,Xiao MEI,Haidi PAN,Yuanxin MA,Wei. WANG. Research progress on the intervention of traditional Chinese medicine in IBS⁃D based on the "SCFAs⁃intestinal barrier" pathway [J]. The Journal of Practical Medicine, 2024, 40(15): 2177-2182.
[4]	Shan′gao HUANG,Yueling WU,Ying. ZHANG. Aiming for the future： The latest advances in targeted therapy for ovarian cancer [J]. The Journal of Practical Medicine, 2024, 40(14): 1901-1907.
[5]	Haixia YUAN,Xinmin HAN,Tianyi CHEN,Yuchen. SONG. Progress on structural abnormalities in the cerebral cortex in children with attention deficit/hyperactivity disorder [J]. The Journal of Practical Medicine, 2024, 40(10): 1455-1459.
[6]	Yadan CHE,Lixia. LI. Reaserch progress on small molecule anti⁃angiogenic drugs for advanced breast cancer [J]. The Journal of Practical Medicine, 2023, 39(22): 2866-2871.
[7]	LIU Hui, HE Caixian, PENG Jiyong, ZHONG Xi, LIAO Kai, YUAN Yawei, ZHENG Ronghui.. Carotid arterial injuries caused by radiotherapy for nasopharyngeal carcinoma：A review [J]. The Journal of Practical Medicine, 2023, 39(10): 1201-1205.
[8]	LI Yanwei, WANG Bin, MIAO Yulu, LI Xiao⁃ jin, ZHANG Yadong, HAN Juan, ZHUANG Pengwei, ZHANG Yanjun.. Research progress of intestinal barrier dysfunction in sepsis [J]. The Journal of Practical Medicine, 2022, 38(7): 799-803.
[9]	ZHANG Ying, WU Yueling.. Immunotherapy incervical cancer：The advent of precision medicine [J]. The Journal of Practical Medicine, 2022, 38(15): 1856-1859.
[10]	WAN Jingfang, CHEN Kehong.. Progress on preventing peritoneal fibrosis in peritoneal dialysis [J]. The Journal of Practical Medicine, 2022, 38(10): 1286-1291.
[11]	LI Liu, YU Jianhua. . Research progress on risk factors and prevention and treatment of AIDS ⁃related cardiovascular diseases [J]. The Journal of Practical Medicine, 2021, 37(20): 2687-2691.

Research progress on mechanism of paeonol in the treatment of intestinal diseases

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 39

Related Articles 11

Recommended Articles

Metrics

Comments